Table 2.
IC50 values determined by non-linear regression of MTT assay data.
|
A549 Human NSCLC Cell Lines
|
||||||
|---|---|---|---|---|---|---|
| Wild Type | shControl | shMer1-G8 | shAxl8-G5 | shAxl9-D3 | ||
| Cisplatin (μM) | IC50 | 6.48 | 8.56 | 3.00 | 0.51 | 3.40 |
| (95% CI) | (4.8 – 8.8) | (6.5 – 11.2) | (2.4 – 3.7) | (0.4 – 0.7) | (2.6 – 4.5) | |
| P<0.05 | NS | - | * | * | * | |
|
| ||||||
| Carboplatin (μM) | IC50 | > 160 | > 160 | 93.4 | 9.13 | ND |
| (95% CI) | ND | ND | (60.1 – 145) | (5.8 – 14.4) | ND | |
| P<0.05 | ND | - | ND | ND | ND | |
|
| ||||||
| Doxorubicin (nM) | IC50 | 34.9 | 69.2 | 71.2 | 2.1 | 13.0 |
| (95% CI) | (18.0 – 67.7) | (45.5–105.4) | (31.2 – 162) | (1.0 – 4.2) | (8.6 – 19.7) | |
| P<0.05 | NS | - | NS | * | * | |
|
| ||||||
| Etoposide (μM) | IC50 | 2.20 | 3.32 | 3.84 | 0.33 | 1.01 |
| (95% CI) | (1.58 – 3.05) | (2.47 – 4.46) | (2.78 – 5.30) | (0.24 – 0.46) | (0.70 – 1.46) | |
| P<0.05 | NS | - | NS | * | * | |
Cumulative data from at least three independent experiments performed in triplicate were analyzed.
*
Significance versus shControl is indicated by non-overlapping confidence intervals (95% CI). Significance could not be statistically evaluated for Carboplatin treated cells because an IC50 was not reached for wild type or shControl cells. Abbreviations are as follows: ND, Not determined; NS, Not significant.